Effect of Sofosbuvir on Length of Hospital Stay in Moderate COVID-19 Cases; a Randomized Controlled Trial
Archives of Academic Emergency Medicine,
Vol. 10 No. 1 (2022),
1 January 2022
,
Page e46
https://doi.org/10.22037/aaem.v10i1.1621
Abstract
Introduction: Efforts to control the COVID-19 pandemic are still on. This study aimed to evaluate the effect of sofosbuvir on length of hospital stay and complications in COVID-19 cases with moderate severity.
Methods: This randomized clinical trial was done on moderate COVID-19 cases, who were admitted to Shohadaye Tajrish Hospital, Tehran, Iran, from 4/2021 to 9/2021. Eligible patients were randomly allocated into two groups of intervention (sofosbuvir) and control, and their outcomes were compared regarding the length of hospital stay and complications.
Results: 100 COVID-19 cases were randomly divided into two groups of 50 patients, as the intervention and control groups. The mean age of patients was 50.56 ± 12.23 and 57.1±14.1 years in the intervention and control groups, respectively (p = 0.02). The two groups were similar regarding distribution of gender (p = 0.15), underlying diseases (p = 0.08), the severity of COVID-19 (p = 0.80) at the time of admission, signs and symptoms (p > 0.05), and essential laboratory profile (p > 0.05). The length of hospital stay in the control and intervention groups was 7.7 ± 4.09 days and 4.7±1.6 days, respectively (p = 0.02). None of our patients needed ICU or mechanical ventilation.
Conclusion: Sofosbuvir may decrease the length of hospital stay of COVID-19 cases with moderate severity, without a significant effect on the rate of intensive care unit (ICU) need and mortality.
- SARS-CoV-2
- Treatment Outcome
- Sofosbuvir
- Duration of Therapy
How to Cite
References
Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. The Lancet infectious diseases. 2020;20(7):773.
Luchsinger LL, Hillyer CD. Vaccine efficacy probable against COVID-19 variants. Science. 2021;371(6534):1116-.
Acharya KP, Ghimire TR, Subramanya SH. Access to and equitable distribution of COVID-19 vaccine in low-income countries. npj Vaccines. 2021;6(1):1-3.
Kwok KO, McNeil EB, Tsoi MTF, Wei VWI, Wong SYS, Tang JWT. Will achieving herd immunity be a road to success to end the COVID-19 pandemic? Journal of Infection. 2021;83(3):381-412.
Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis. Annals of Medicine. 2022;54(1):516-23.
Arsenault C, Gage A, Kim MK, Kapoor NR, Akweongo P, Amponsah F, et al. COVID-19 and resilience of healthcare systems in ten countries. Nature Medicine. 2022:1-11.
Hill A, Wang J, Levi J, Heath K, Fortunak J. Minimum costs to manufacture new treatments for COVID-19. Journal of Virus Eradication. 2020;6(2):61-9.
Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Annals of internal medicine. 2015;162(6):407-19.
Elfiky AA, Azzam EB, Shafaa MW. The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico. Molecular Diversity. 2021:1-11.
Chan H-T, Chao C-M, Lai C-C. Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: a meta-analysis. Journal of Infection. 2021;82(4):e34-e5.
Sacramento CQ, Fintelman-Rodrigues N, Temerozo JR, Da Silva AdPD, Dias SdSG, Da Silva CDS, et al. In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. Journal of Antimicrobial Chemotherapy. 2021;76(7):1874-85.
Hsu C-K, Chen C-Y, Chen W-C, Lai C-C, Hung S-H, Lin W-T. The effect of sofosbuvir-based treatment on the clinical outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. International Journal of Antimicrobial Agents. 2022:106545.
Hill A, Simmons B, Gotham D, Fortunak J. Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C. Journal of virus eradication. 2016;2(1):28-40.
Chien M, Anderson TK, Jockusch S, Tao C, Li X, Kumar S, et al. Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19. Journal of proteome research. 2020;19(11):4690-7.
Beck BR, Shin B, Choi Y, Park S, Kang K. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Computational and structural biotechnology journal. 2020;18:784-90.
Nourian A, Khalili H, Ahmadinejad Z, Kouchak HE, Jafari S, Manshadi SAD, et al. Efficacy and safety of sofosbuvir/ledipasvir in treatment of patients with COVID-19; A randomized clinical trial. Acta Bio Medica: Atenei Parmensis. 2020;91(4). e2020102
Roozbeh F, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Merat S, Wentzel H, et al. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. Journal of Antimicrobial Chemotherapy. 2021;76(3):753-7.
Li K, Fang Y, Li W, Pan C, Qin P, Zhong Y, et al. CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19). European radiology. 2020;30(8):4407-16.
National Guideline for Diagnosis and Treatment of COVID 19 vtEN, https://treatment.sbmu.ac.ir/uploads/7__dastoor_flochart_treatment_covid_19.pdf. National Guideline for Diagnosis and Treatment of COVID 19. 2021.
Eslami G, Mousaviasl S, Radmanesh E, Jelvay S, Bitaraf S, Simmons B, et al. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. Journal of Antimicrobial Chemotherapy. 2020;75(11):3366-72.
Abbaspour Kasgari H, Moradi S, Shabani AM, Babamahmoodi F, Davoudi Badabi AR, Davoudi L, et al. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. Journal of Antimicrobial Chemotherapy. 2020;75(11):3373-8.
Sayad B, Khodarahmi R, Najafi F, Miladi R, Mohseni Afshar Z, Mansouri F, et al. Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial. Journal of Antimicrobial Chemotherapy. 2021;76(8):2158-67
- Abstract Viewed: 622 times
- pdf Downloaded: 423 times